B+
Bull case
30%
Probability
Target price
$190.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
INSM
InsmedBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 results support a strong BRINSUPRI launch, the raised revenue guide improves near-term visibility, and ARIKAYCE label expansion plus TPIP Phase 3 programs provide additional upside optionality [#SEC-8K-2026-08-06].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.4.
What can break
ARIKAYCE label expansion and the brensocatib Japan decision remain pending, while evolving U.S. policies may affect international launch timing [#SEC-8K-2026-08-06].
Momentum
52
Value
41
Sentiment
79
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $140.00 · Bull $190.00 · Bear $100.00Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $200.18
Why
Momentum52 · Δ7d +3.3
Value41 · Δ7d 0.0
Sentiment79 · Δ7d +3.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +3.4.
Contradictions & invalidation
- • ARIKAYCE label expansion and the brensocatib Japan decision remain pending, while evolving U.S. policies may affect international launch timing [#SEC-8K-2026-08-06].
- • BRINSUPRI launch momentum may decelerate or fail to support the raised $1.25-$1.40 billion 2026 guidance.
- • The stock already reflects substantial commercial and pipeline expectations.
Catalyst clock
2026-08-06
Q2 2026 results and raised BRINSUPRI guidance
Lead driver: Sentiment · See AI snapshot
Momentum
52
9% active weight
Current posture
7d trendImproving
Δ7d
+3.3
Δ21d
-4.3
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
79
62% active weight
Current posture
7d trendImproving
Δ7d
+3.4
Δ21d
+6.1
Why this grade
Composite grade B. Momentum 52.5 / Value 41.2 / Sentiment 79.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$140.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$100.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$28.02B
Beta
1.11
Shares Out
218.38M
P/E (TTM) · Derived
-20.0
P/S (TTM)
83.59
P/FCF (TTM) · Derived
-32.79
Rev YoY
+296.1%
EPS YoY
-96.4%
Gross Margin
+82.8%
Op Margin
-71.4%
Net Debt
-$674.06M
Current Ratio
3.72
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data